Tonix Pharmaceuticals Appoints Irina Ishak As General Counsel To Oversee Legal, Governance, And Compliance Functions Starting Dec 8, 2025

Tonix Pharmaceuticals Holding Corp., a fully integrated commercial-stage biotechnology company, announced the appointment of Irina Ishak as General Counsel, effective December 8, 2025. In this role, Ms. Ishak will oversee Tonix’s legal, corporate governance, and compliance functions. Seth Lederman, M.D., President and CEO of Tonix, welcomed Ishak to the leadership team, highlighting her extensive experience in corporate and commercial law across public and private life sciences companies. 

He emphasized that her expertise in complex transactions, governance, and public company matters will support Tonix as it commercializes its products, advances its pipeline, manages partnerships, and executes its long-term strategy. Ms. Ishak joins Tonix from Lowenstein Sandler LLP, where she served as Senior Counsel since 2013 and had advised Tonix since 2017 on a range of strategic matters, including financings, licensing transactions, commercial agreements, employment contracts, and corporate governance. In addition to her work with Tonix, she has acted as outside general counsel and advisor to several public and private life sciences companies and investors. 

Previously, she was Senior Director, Legal, and Assistant Corporate Secretary at Savient Pharmaceuticals, Inc., which developed and launched KRYSTEXXA® (pegloticase), the FDA-approved biologic treatment for chronic gout in adults. Early in her career, Ms. Ishak worked as a corporate associate at Fried, Frank, Harris, Shriver & Jacobson LLP. She earned her J.D. from New York University School of Law and her B.A., with highest honors, from Rutgers College in New Brunswick, New Jersey.

Ms. Ishak expressed her enthusiasm about joining Tonix, noting that the company has recently launched the first FDA-approved therapy for fibromyalgia in over 15 years. She highlighted the opportunity to help expand Tonix’s scientific innovations into additional therapeutic areas and looks forward to partnering with the CEO, leadership team, and Board to support the company’s next phase of growth.